NEW YORK (GenomeWeb) – Danish miRNA biomarker firm Exiqon today reported its first quarter revenues were up 2 percent year over year.

The company reported DKK32.5 million ($6.0 million) in revenues for the three months ended March 31, compared to DKK31.8 million in the year-ago quarter. It attributed the gain to continued organic growth in its Life Sciences product sales, which rose 5 percent year over year, driven by new products. Exiqon's Services business was down 19 percent year over year during the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.